Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)

Young Woong Won, Jung Hye Kwon, Soon Il Lee, Sung Yong Oh, Won Seog Kim, Seok Jin Kim, Jong Ho Won, Kyoung Ha Kim, Seong Kyu Park, Jin Seok Kim, Cheolwon Suh, Dok Hyun Yoon, Joon Seong Park, Min Kyoung Kim, Hawk Kim, Hye Jin Kang, Yeung Chul Mun, Jae Yong Kwak, Hyo Jung Kim, Hyeon Seok Eom

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Ethnic and regional differences in the epidemiology and pathological aspects of Hodgkin's lymphoma (HL) between Western and Asian patients may be associated with differences in clinical features and prognosis. We retrospectively analyzed the clinical and histopathological characteristics, therapeutic outcomes, and prognostic factors of 539 HL patients treated at 16 centers in Korea. We found that the incidence of histological subtypes of HL in Korea was similar to that in Western and other Asian countries. However, the incidence peaked between 16 and 30 years of age, unlike the bimodal age distribution seen in Western countries. In patients with stage I-IIA non-bulky disease, the complete response (CR) rate was similar between combined modality therapy and chemotherapy alone (93% vs. 84%, P = 0.44), and there was no difference in relapse-free survival (RFS) and overall survival (OS). Patients with stage I-II disease plus unfavorable factors and those with advanced-stage disease treated with combination chemotherapy regimens had an overall CR rate of 77%, with no difference between doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and non-ABVD regimens (77.2% vs. 76.8%, P = 0.95). Among those patients who achieved final CR, there was no significant difference in RFS or OS between those who achieved interim CR and PR. Only the presence of B symptoms was independently predictive of a shorter RFS. Age > 45 years, Eastern Cooperative Oncology Group 2-4, and B symptoms were independent risk factors for death. Although the incidence of HL was lower in Korea than in Western countries, the distribution of morphological subtypes, treatment outcomes, and patient prognosis were similar.

Original languageEnglish
Pages (from-to)223-233
Number of pages11
JournalAnnals of Hematology
Issue number2
StatePublished - Feb 2012

Bibliographical note

Funding Information:
Acknowledgment This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A062260).


  • Hodgkin's lymphoma
  • Outcome
  • Prognosis
  • Treatment


Dive into the research topics of 'Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)'. Together they form a unique fingerprint.

Cite this